One idea to fix pharma’s superbug problem: debt
By now it’s well understood that the drug industry’s antimicrobial pipelines are insufficient in the context of society’s need for new armaments against superbugs. And it’s widely known that startups in the space have found it nearly impossible to attract investors.
The World Health Organization is offering a potential solution: Let us loan you the money.
As Peter Beyer, a senior advisor in the WHO antimicrobial resistance division, explained to STAT’s Ed Silverman, the group is working with the European Investment Bank to start a $1 billion fund. With that fund, they’d aim to rescue biotech companies from the valley of death that so often scuttles new antibiotic ideas.
Under that model, a company on the verge of Phase 3 could draw on a credit line, Beyer said, using the money to wrap up development and, ideally, bring a much-needed treatment to market.
Read more.
The World Health Organization is offering a potential solution: Let us loan you the money.
As Peter Beyer, a senior advisor in the WHO antimicrobial resistance division, explained to STAT’s Ed Silverman, the group is working with the European Investment Bank to start a $1 billion fund. With that fund, they’d aim to rescue biotech companies from the valley of death that so often scuttles new antibiotic ideas.
Under that model, a company on the verge of Phase 3 could draw on a credit line, Beyer said, using the money to wrap up development and, ideally, bring a much-needed treatment to market.
Read more.
.png)
No hay comentarios:
Publicar un comentario